SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Biotech Valuation
An SI Board Since February 1999
Posts SubjectMarks Bans Symbol
52157 680 3 CRSP
Emcee:  Biomaven Type:  Moderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
51253OK - the previous post was likely wrong - those are list prices, and we don'Biomaven111/28/2019
51252Miljenko's Japanese pricing (819.20 yen), if accurate, would support your orretiredactuary-11/28/2019
51251Roxadustat gets national reimbursement in China. Price is either around $1,200 Biomaven211/28/2019
51250Development of antiviral resistance: phys.orgnigel bates-11/26/2019
51249COGS should be reasonable (cheap), as future majority of the API would be producMiljenko Zuanic-11/21/2019
51248The manufacturing process for pills is largely automated, meaning that labor cosArt Bechhoefer-11/21/2019
51247Anyone estimate what the COGS for roxa? Is it expensive to make or cheap (like IRWIN JAMES FRANKEL-11/21/2019
51246It is about $2.4K/y (100 mg dose), which is below expectation. But, it is affordMiljenko Zuanic-11/20/2019
51245The prices for roxadustat in Japan look reasonable and affordable. Certainly leArt Bechhoefer-11/20/2019
51244Evrenzo (Roxa) launches in Japan today. NHI priced at 387.40 yen for 20 mg tableJoe Wesley211/20/2019
51243FGEN data need more explanations. There are several factors that are not even mArt Bechhoefer-11/18/2019
51242If anyone's looking for a cheap biotech that could grow explosively, take a Gary Mohilner-11/16/2019
51241Thanks very much for a complete answer Tuck. That helps a lot. Perhaps the comA.J. Mullen-11/16/2019
51240Hi, Ashley, Short answer: decision likely 6 months to a year from filing. It dtuck111/15/2019
51239Yes, I see now the extra deaths were not only in NDD. FGEN aim to submit the NDA.J. Mullen-11/15/2019
51238Invitae was up 10% at one time today, pairing with Apple to link biometric data A.J. Mullen111/15/2019
51237I get that ALL the trials are about safety. You are saying safety is path indepsemi_infinite -11/14/2019
51236Again, you are talking about secondary efficacy end-point, issue is safety. NonMiljenko Zuanic-11/14/2019
51235In most recent trial wrt dosing specificity Proportion of total time of Hb = 10semi_infinite -11/14/2019
51234We do not have many details from Pyrenees trial (to go into *premature* explanatMiljenko Zuanic-11/14/2019
51233The gfr cutoffs for stage 4 and 5 (5 being ESRD) are <30 and >15 for stagesemi_infinite -11/14/2019
51232Ashley, you are talking about NDD, Pyrenees (my comments) was stable DD pts thatMiljenko Zuanic-11/14/2019
51231It is not conspiracy, but it is fishy that we learned about results this way! AgA.J. Mullen111/14/2019
51230Please, can somebody confirm...is Blackrock that big? 2.46 T $ ? old.nasdaq.com Thehammer-11/14/2019
51229<stable dialysis> is standard language in trial name and ALL DD are end-stMiljenko Zuanic-11/14/2019
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News